Shanghai Genomics announces discovery collaboration

STORY UPDATE
TOKYO—November 21, 2007—As Chinese affiliate Shanghai Genomics prepares to initiate a Phase I clinical trial, GNI Ltd. announced it has received IND approval for F351, its candidate drug for liver fibrosis/cirrhosis. The approval comes just weeks after the companies received regional patent rights to the drug from China's Patent and Trademark Office. According to Dr. Ying Luo, CEO for both companies, liver disease is a major healthcare challenge in Asia.
 
 
Tokyo—Shanghai Genomics Inc., the China-based affiliate of GNI and one of China's leading biotech companies, has agreed to collabo­rate on a drug discovery research project with Centocor, Inc. a U.S.-based biopharmaceutical company with a global business in monoclo­nal antibody production and tech­nology. The collaboration, which will involve biological research aimed at understanding inflam­matory signaling pathways, will initially last for a period of 18 months.
 
"Shanghai Genomics is delighted to be collaborating with Centocor on this exciting project," says Ying Luo, president and CEO of Shanghai Genomics and presi­dent and COO of GNI. "This is yet another validation of the model we have refined with GNI, where we are the first company to combine innovative Western science with cost-efficient research capabilities in China, and access to the Chinese and Japanese pharmaceutical mar­kets."
 
Shanghai Genomics will use its expertise in protein purification and cell-based interaction assays to explore receptor protein inter­actions and intracellular signal­ing cascades with Centocor. In particular, the research will focus upon the areas of inflammation and oncology.
 
Utilizing what it calls a "highly efficient yet cost-effective technol­ogy platform," Shanghai Genomics has entered into and completed many research-based collabora­tions with international partners such as Centocor. These collabora­tions with international partners form a crucial pillar of Shanghai Genomics' business and comple­ment the drug discovery work the company conducts with GNI.
 
Shanghai Genomics was found­ed in August 2001, by returned overseas biotech veterans, Drs. Ying Luo and Jun Wu, with fund­ing from two Chinese venture capital funds—Shanghai Venture Capital Company and Shanghai Zhangjiang Hi-Tech Park Corp.
 
In July 2005, Shanghai Genomics became an affiliate of GNI, a Tokyo headquartered, Asia-centered bio­pharmaceutical company focused on the field of integrated systems pharmacology. Using approved methods, GNI has successfully mapped the gene regulatory net­works via a complex process of reverse-engineering. Furthermore, GNI maintains that it is the only company to have developed the technology required to apply this data to drug development and dis­covery.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue